Article

Pelcitoclax/Osimertinib Combo Shows Preliminary Effiacy in EGFR+ NSCLC

The combination of osimertinib plus pelcitoclax demonstrated an acceptable safety profile and preliminary efficacy at the recommended phase 2 dose in patients with EGFR-positive non–small cell lung cancer that is resistant to third-generation EGFR inhibitors or treatment naïve.

The combination of osimertinib (Tagrisoo) plus pelcitoclax (APG-1252) demonstrated an acceptable safety profile and preliminary efficacy at the recommended phase 2 dose in patients with EGFR-positive non–small cell lung cancer (NSCLC) that is resistant to third-generation EGFR inhibitors or treatment naïve, according to results of a phase 1b trial (NCT04001777) that were presented at the 2021 World Conference on Lung Cancer.

“Combination treatment with APG-1252 and osimertinib at the recommended phase 2 dose was safe and well tolerated,” Li Zhang, MD, of State Key Laboratory in South China Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China, said during a presentation of the data. “Preliminary efficacy of this combination was observed in some patients with osimertinib resistance.”

Although osimertinib is a standard agent for the treatment of patients with EGFR-mutant NSCLC, resistant develops in most instances and necessitates additional treatment options for later-line disease management. Pelcitoclax is a novel dual BCL-2/BCL-xL inhibitor with evidence of antitumor activity, less platelet killing versus navitoclax, and potential synergism with osimertinib in preclinical models.

In the single-arm trial, the key objectives were safety and establishing the recommended phase 2 dose of pelcitoclax. In the dose-determination portion of the study, 7 patients received 240 mg of once-weekly intravenous pelcitoclax, and 6 patients were given a 160-mg weekly dose. All patients received daily oral osimertinib at 80 mg. In the expansion cohort, 20 patients with resistance to third-generation EGFR tyrosine kinase inhibitors who were also pretreated with platinum chemotherapy (Arm 1) and 23 patients with osimertinib-naïve NSCLC (Arm 2) were given the recommended phase 2 dose of 160 mg of weekly pelcitoclax plus 80 mg of daily osimertinib.

There was 1 dose-limiting event of grade-4 thrombocytopenia in the group receiving pelcitoclax at 240 mg (n = 7). In those receiving 160 mg (n = 49), there were no thrombocytopenia events of grade 3. Additionally, heightened levels of alanine aminotransferase (ALT; 46.9% vs 100.0%) and aspartate aminotransferase (AST; 51.0% vs 100.0%) were less frequent in those receiving the lower versus higher dose of pelcitoclax, respectively.

All-grade adverse events (AEs) occurring in the entire cohort (n = 56) were AST increased (87.5%), ALT increased (53.6%), platelet count decreased (32.1%), blood creatinine increased (23.2%), amylase increased (19.6%), white blood cell count decreased (19.6%), anemia (16.1%), and decreased appetite (12.5%). Grade 3 events occurring in the 160-mg group included AST increased (2.0%), ALT increased (2.0%), and white blood cell count decreased (2.0%). In the 240-mg group, grade 3 events were noted for AST (42.9%), ALT (28.6%), platelet count decreased (57.1%).

Preliminary efficacy showed an unconfirmed partial response (PR) rate of 15.0% and a confirmed PR rate of 5.0% in Arm 1, with corresponding rates of 59.1% and 36.4% in Arm 2. Stable disease was noted in 65.0% in Arm 1 and 36.4% in Arm 2, for disease control rates of 80.0% and 95.5%, respectively. Of note, no confirmed or unconfirmed responses were recorded for the 240-mg dose group in the dose-determination phase versus 1 unconfirmed partial response in the 160-mg group.

“Three patients with EGFR exon 20 insertion mutations in Arm 2 experienced tumor shrinkage. We are planning to open a new arm to enroll these patients separately,” Zhang said.

To conclude, Zhang added that there were no significant differences in the pharmacokinetic profiles of APG-1252 plus osimertinib when compared with each as monotherapy.

Reference

  1. Zhang L, Zhao H, Ma Y, et al. Phase 1b Study of Pelcitoclax (APG-1252) in Combination With Osimertinib in Patients With EGFR TKI-Resistant NSCLC. Presented at: 2021 World Conference on Lung Cancer; September 8-14, 2021. Virtual. Abstract MA02.06.
Related Videos
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, on progression patterns and subsequent therapies after lorlatinib in ALK-positive NSCLC.
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss preclinical CNS data for the ROS1 inhibitor zidesamtinib.
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss data for zidesamtinib in ROS1-positive non–small cell lung cancer.
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss data for NVL-655 in ALK-positive NSCLC and other ALK-positive solid tumors.
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss testing for ALK-positive and ROS1-positive non–small cell lung cancer.
Nicolas Girard, MD
Sally Lau, MD
Andrea Wolf, MD, MPH
Jacob Sands, MD
Marina Chiara Garassino, MD